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Abstract
The goal of contemporaryr esearch in pemphigus vulgaris and pemphigus foliaceus is to achieve and maintain clinical
remission without corticosteroids. Recent advances of knowledge on pemphigus autoimmunity scrutinize old dogmas, resolve
controversies, and open novel perspectives for treatment. Elucidation of intimate mechanisms of keratinocyte detachment and
death in pemphigus has challenged the monopathogenic explanation of disease immunopathology.O ver 50 organ-speciﬁc and
non-organ-speciﬁc antigens can be targeted by pemphigus autoimmunity,i ncluding desmosomal cadherins and other
adhesion molecules, PERP cholinergic and other cell membrane (CM) receptors, and mitochondrial proteins. The initial
insult is sustained by the autoantibodies to the cell membrane receptor antigens triggering the intracellular signaling by Src,
epidermal growthf actor receptor kinase, protein kinases Aa nd C, phospholipase C, mTOR, p38 MAPK, JNK, other tyrosine
kinases, and calmodulin that cause basal cell shrinkage and ripping desmosomes off the CM. Autoantibodies synergize with
effectorso fa poptotic and oncotic pathways, serine proteases, and inﬂammatoryc ytokines to overcome the natural resistance
and activate the cell death program in keratinocytes. The process of keratinocyte shrinkage/detachment and death via
apoptosis/oncosis has been termed apoptolysis to emphasize that it is triggered by the same signal effectorsa nd mediated by
the same cell death enzymes.T he natural course of pemphigus has improved due to as ubstantial progress in developing of the
steroid-sparing therapies combining the immunosuppressive and direct anti-acantholytic effects. Further elucidation of the
molecular mechanisms mediating immune dysregulation and apoptolysis in pemphigus should improveo ur understanding of
disease pathogenesis and facilitate development of steroid-free treatment of patients.
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Introduction
Autoimmune pemphigus is al ife-threatening muco-
cutaneousb listeringd isease associated with IgG
antibodiest argeting several types of keratinocyte
antigens and eliciting epidermal clefting (acantholysis)
via intracellular signalingactivating apoptotic enzymes
(apoptolysis) [1]. Systemic administration of gluco-
corticosteroid hormones is essential to establish
controlo fd iseased uring the acute stage [2]. Although
glucocorticosteroid treatment is life-saving,i tm ay
causes everes idee ffects, including death[ 3,4].
Therefore,p emphigus patients need drugs thatc an
replace glucocorticosteroids. Thed evelopment of
non-steroidalt reatment has been hampered by al ack
of clear understandingo ft he mechanisms leading to
keratinocyte detachment and death in pemphigus.
This overview of recent advances in the knowledge of
pemphigusa utoimmunity challengest he existing
dogmas, helps resolve old controversies, andi dentiﬁes
newp erspectives fort reatment.I te ncompasses
knowledge on pemphigusv ulgaris (PV)a nd pemphi-
gus foliaceus (PF), but speciﬁcally excludes reports
on paraneoplastic pemphigus, or PNP, originally
described by Anhalte ta l. [5], because this disease is
not related to PV and PF.T he notion that PNP
represents av ariant of classical pemphigus stems from
the facts that patients with PV or PF sometime have
concomitant neoplasms [6–8]a nd that some patients
with PNP develop anti-desmoglein (Dsg) 1a nd/or 3
antibodies—the hallmark of classical pemphigus [9].
In fact, PNP represents only one manifestation of the
heterogeneousa utoimmune syndrome—termed para-
neoplastic autoimmune multiorgan syndrome
(PAMS)—targeting both tegumental epithelium and
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pemphigus, PAMS has an overall mortality more than
90% despite therapy,w ith progressive respiratory
failure with clinical features of bronchiolitis obliterans
being them ostf requentc ause of death[ 11].
Sloughing of bronchial epithelial cells contributes to
the occlusion of the small airways that provides a
potential mechanismf or the respiratoryf ailure[ 10].
Patients with PAMS develop mucocutaneous lesions
that resemble pemphigoid,e rythemam ultiforme,
lichen planus, andg raft vs. host disease, as well as
the pemphigus-like variant that was termed PNP in
the index patient with PAMS.O ral mucosal lesionso f
painful, progressive stomatitis are the hallmark of the
diseasea nd usually are the initial manifestation of
PAMS [12]. The proposedp athogenesis of PAMS
continues to evolve. It is clear that the immunopatho-
logicm echanisms differ appreciably from those
responsible for the lesionso fc lassical pemphigus.
The spectrumo fP AMSi ncludes patients with disease
predominantly or exclusively mediated by the cell-
mediated autoimmunity effectorsa nd those with both
autoantibodies and cellular cytotoxicity [13].
Pemphigusa utoantigens
Following the discoveryo fI gG autoantibodies in
patients with PV [14]a nd PF [15], numerous
attempts haveb een madet oi dentify targeteda ntigens.
The patient’s serum and isolated IgG fraction were
utilized in the immunoprecipitation and immunoblot-
ting experiments using the epidermal or keratinocyte
culturep roteins as well as saliva andu rine as
substrates. Although the low-sensitivity approaches,
such as ﬂuorography with metabolically labeled
keratinocyte proteins preabsorbedw ith human
serum [16], demonstrated single protein bands,a
more sensitiveb ut less speciﬁc immunoblotting
technique revealed more thanadozen of targeted
keratinocyte proteins [17]. An enhanced sensitivity
immunoprecipitation assay demonstrated that differ-
ent PVor PF patients producea ntibodies recognizing
both commona nd unique antigens[ 18].
Representative imageso fp rotein bands recognized
by PVandP Fs era are shown in Figure 1. The full list
of “pemphigus antigens” reportedt od ate contains
over4 0p rotein bands with apparent molecular
weights (MWs) of 12, 18, 25, 30, 33, 35, 38, 40, 45,
47, 50, 52, 55, 57, 59, 60, 62, 66, 67, 68, 70, 75, 78,
80, 85, 95, 100, 102, 105, 110, 112, 120, 130, 140,
160, 170,180, 185/190, 210, and 260kD [16,18–37].
Indeed,s ome of these bands mayi nclude the same
polypeptides migrated with slightly different MWs,
and vice versa, some mayi nclude two or more
similarlys ized but distinct antigens. Fori nstance, in
additiont ot he 130kDD sg 3, PV patients
develop antibodies recognizing yet unidentiﬁedp ro-
tein(s) of thes ame1 30kD MW in Dsg 3
2 / 2
keratinocytes [18] and peripheralb lood mononuclear
cells[ 38].
Identiﬁcation of the nature of proteins targeted by
pemphigus autoimmunity is as ubject of intense
research. Originally,i tw as assumed that the proteins
with the MW of approximately 60kD or less are
“contaminating”k eratinst hatd on ot represent
meaningful targets.H owever, recent studies demon-
strated that only 2% of pemphigus and normal sera
contain anti-keratin antibodies [39]. Furthermore, a
66kD antigen recognized by PV IgG—am embrane
glycoproteinc omposed of two apparently identical
subunits of 33kD—was used to raise rabbit antibody
that induced PV-likep henotype in neonatal mouse
[27]. Nevertheless, the candidates for the pathophy-
siologically relevant PVand PF antigens were selected
among af ew bands migratingw ith ah igherM W,
wherein the 130 and 160 polypeptides were most
commonly seen [16,29]. The antigens with these
MWs were identiﬁed as Dsg 3[ 17] and Dsg 1[ 40],
respectively. Thereafter, exploration of the nature of
pemphigusa ntigensh as been hampered by a
simplistic (or“ monopathogenic” [41]) explanation
of pemphigus pathophysiology through the “Dsg
compensation” hypothesis placing Dsg 1/3 in the
center of the pathophysiologic loop [42].
The Dsgc ompensation hypothesis maintains that
anti-Dsg 1a nd 3a ntibody proﬁles in pemphigus sera
and the normal epidermal distributions of Dsg 1a nd 3
determine the sites of blisterf ormation and that
eitherD sg 1o rD sg 3a lone is sufﬁcientt om aintain
keratinocyte adhesion [42]. The threep ostulates of
this hypothesis are as follows: (1) in the superﬁcial
epidermis of PF patients, where Dsg 1w ithout Dsg 3
is expressed, anti-Dsg 1a ntibody alone can cause
blisters;( 2) Dsg 3a ntibodya lone is sufﬁcientt oc ause
Figure1. Characterizationof anti-keratinocyteantibodyproﬁlesof
PVand PF sera by immunoprecipitation with proteins from cultures
of human epidermal keratinocytes resolvedb y7 .5% SDS-PAGE.
Modiﬁed from Ref.[ 18].
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lacks Dsg 1; and (3) skin lesionsi nP Vp atients
develop when both Dsg 1a nd Dsg 3a ntibodies are
present. The major ﬂaw of this hypothesis is an
assumptiont hatt he integrity of thes tratiﬁed
squamous epithelium enveloping skin ando ral
mucosa relies entirely on Dsg 1a nd 3m olecules. If
that would be the case,t he epidermis would have
disintegrated to as ingle cell suspension in the PV
patientsw ho develop both anti-Dsg1a nd 3a ntibodies
(Figure 2).
The monopathogenic explanation of localization of
intraepidermal clefts in PV and PF through Dsg
compensation hypothesis ignorest he complexity of
homo- andh eterophilic interactionso fs even known
desmosomal cadherins, i.e. Dsg 1–4and desmocollin
(Dsc)1 –3.I nr eality,D sg 3a lone cannot sustain
epidermal cohesion. This is evidentf rom the facts that
Dsg 3c annot compensate for al oss of Dsc 3i nt he
conditional Dsc 3
null mutant mouset hate xhibits
suprabasal acantholysis ando verts kin blistering
[43]. Furthermore, the in vitro experiments demon-
strated that extracellular domain of Dsg 3m ediates
only aw eak homophilica dhesion [44]. Lack of skin
blistersi np atientsw iths triate palmoplantar kerato-
derma featuring ad eletion mutation in the extracellu-
lar domain of Dsg 1a nd in micew ith engineered or
spontaneous mutations of Dsg3(reviewed in [45,46])
clearly indicate that the integrity of epidermis does
not depend solely on Dsg 1a nd 3. The electron
microscopic studies demonstrated that keratinocytes
deprived of endogenous production of Dsg1o r3d ue
to gene silencing via RNA interferencec ontinue to
formd esmosomes [47]. Apparently,t he redundancy
of desmosomal cadherins renderst he external integu-
ments ufﬁcient integrity and durability.
The ﬁrst evidence that keratinocyte antigens other
than Dsg 1a nd 3a re pathophysiologically relevant
in pemphigus was provided by experiments showing
the ability to induce suprabasal acantholysis andg ross
skin blistersi n Dsg3
2 / 2 neonates by passivet ransfer of
PV patients’ antibodies[ 48]. In this model, murine
epidermis lacked Dsg 3a nd the passively transferred
PV IgGs lacked anti-Dsg1antibody.H ence, the
injected PVantibodiest hat caused blistersc ouldt arget
only the non-Dsg 1a nd 3a ntigenst hat mediated
and/or regulated keratinocyte adhesion. This obser-
vation promptedf urther investigations into the nature
of pemphigusa ntigens( reviewed in [41]). By now,
over 50 humanp roteinsh ave been reported to
speciﬁcally react with pemphigus IgG (Table I). In
addition to the known desmosomal cadherins and
several othert ypes of adhesion molecules,t he hitherto
identiﬁed pemphigus antigens include cell membrane
(CM)r eceptors, immunologic/hematologic antigens,
neuronal/oncologic antigens, and thyrogastric cluster
antigens.
Of particulari nterest is ar ecently discovered
autoimmunity against an ovelm embero ft he
peripheralm yelin protein( PMP)-22/gas3f amily
termed PERPa sw ell as the structurallyr elated
PMP-22 [49,50]. Knockoutm icel acking PERP
display ap henocopy of PV [51], which gaver ise to a
notion that the biologic function of PERPi sl imited to
desmosomal stabilization [52]. However, PERP is
expressed in various types of cells that do not form
desmosomes [53], which argues against its exclusive
biologic function in desmosomal adhesion. Recent
ﬁndings and its putative tetraspan transmembrane
topology implicate ar ole for PERPi nt he extrinsic
apoptotic pathway that involves direct interaction
between adaptor proteins andt he receptor complexes
activating caspase 8, i.e. PERPi sanovel cell death
receptor [54]. Hence, dissolution of desmosomes and
PV-like intraepidermal split in Perp
2 / 2 mice appar-
ently result from aberranti nside-out signalinga long
the altered cell death pathways.
In ar adioimmunoprecipitation assay of 34 PV and
6P Fs erum, 85% of patientsp recipitated keratino-
cyte acetylcholine (ACh) receptors( AChRs) [48].
Figure 2. The imaginarya ppearances of epidermis in the skin of PV patients that produce both Dsg 1a nd 3a ntibodies based on the
postulates of Dsg compensationh ypothesis vs.r eal appearance of lesional epidermis in PV patients.
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both muscarinic (mAChR) and nicotinic (nAChR)
classes, and these receptorsr egulate cell adhesioni na
synergistic fashion (reviewed in [55,56]).B locking of
eitherc lass of keratinocyte AChRs leads to disas-
semblyof desmosomal and adherencej unctions due to
phosphorylation of desmosomal and classical cadher-
ins, respectively,w hereas cholinergic agonists prevent
cell detachment by activating protein phosphatases
and upregulating expression of the cadherin genes.
Targeting of a 3n AChR by pemphigus antibodyw as
discovered in ap atient with coexistent PF,m yasthenia
gravis,a nd thymoma[ 57]. Indeed,p emphigus
patientso ccasionallyd evelop myasthenia gravis, an
anti-nAChR autoimmune disease( reviewed in [6]).
Basedo nt he epitope-spreading model [58], patients
with myasthenia gravis might produce antibodies
binding other memberso fa no verall homologous
nAChR protein gene family (reviewed in [59]).
The types of otherA ChRs targetedb yp emphigus
autoimmunity have been investigated using various
experimental approaches. Reactivity of PV IgG with
the mixedm uscarinic and nicotinic a 9A ChR was
observed in the immunoﬂuorescence blockinge xper-
iments, wherein stainingo fm onkey esophagus by
rabbit anti-a 9a ntibodyw as preventedd ue to
preincubation of the substrate with PV antibodies
[36]. Recently,t he proteomics approach has demon-
strated that PVantibodiesr eact with a 10 subunit that
can be ap arto ft he pentameric a 9 a 10 nAChR
(unpublished).T herefore,t he binding sitef or a 9
antibody in the heteromeric a 9 a 10 nAChR also can
be hindered by anti-a 10 antibody present in PV sera.
Whena dded to keratinocytem onolayer,a nti-a 9
antibody produced acantholysis [36],i ndicating that
the alteration of either a 9o r a 10 subunit inactivates
functioning of the a 9 a 10 channel coupled to the
regulation of keratinocyte adhesion.
Using the proteomics technology,t wo research
groups have independently demonstrated that pem-
phigus autoimmunity targetst he M 1 subtype of
keratinocyte mAChRs[ 60,61]. The protein array
technology also identiﬁedM 2 ,M 4 ,a nd M 5 mAChR
subtypes as targets of pemphigus autoimmunity [61].
Probingo fk eratinocyte l gt11 cDNAl ibraryw ith the
PV IgG eluted from a7 5kDb and that stained
epidermis in pemphigus-like intercellularp attern and
caused acantholysis in the keratinocyte monolayers
revealed an ovel type of AChRs, termed pemphaxin
(a.k.a.a nnexin 9) [62].A pparently, theA ChR-
binding pemphaxin is oneo ft he annexin protein
family memberst argeted by pemphigus autoimmunity
[63]. Most recently,i th as been reported that patients
with endemic formo fP Fh avea utoantibodies to
pilosebaceous units and to their surrounding neuro-
vascular packages[ 64].
Al arge spectrumo fo rgan-non-speciﬁc antigens
that can be targeted by pemphigusa utoimmunity
Table I. Self-antigensr ecognized by pemphigus IgGs.
Antigen Reference
Adhesion molecules
Collagen XVII (a.k.a. BPAG2) [340]
Desmocollin 1[ 124]
Desmocollin 2[ 124]
Desmocollin 3[ 125]
Desmoglein 1[ 40]
Desmoglein 2[ 341]
Desmoglein 3[ 17]
Desmoglein 4[ 342]
Desmoplakin 1[ 343]
Desmoplakin 2[ 343]
E-cadherin [344]
Intercellular adhesion molecule 1[ 49]
Plakoglobin (a.k.a. g -catenin) [345]
Plakophilin-3 [346]
Platelet/endothelial cell adhesion molecule [49]
Cell membrane receptors
Acetylcholine receptor [48]
Acetylcholine receptor, M 1 muscarinic [60,61]
Acetylcholine receptor, M 2 muscarinic [61]
Acetylcholine receptor, M 4 muscarinic [61]
Acetylcholine receptor, M 5 muscarinic [61]
Acetylcholine receptor, a 3n icotinic [57]
Acetylcholine receptor, a 9n icotinic [36]
Acetylcholine receptor, a 10 nicotinic (Unpublished)
Acetylcholine receptor, 1 nicotinic (Unpublished)
Annexins [63]
Fc1 RIa [347]
Neuronal voltage-gated K
þ channel [348]
Pemphaxin [a.k.a. annexin 9) [62]
Taurine transporter-like molecule [348]
Thrombospondin receptor [49]
TNF receptor superfamily member 5[ 49]
Transmembrane 4s uperfamily
(a.k.a. tetraspanin family; CD37)
[49]
PERP [50]
Parathyroid hormone 1r eceptor [50]
TGF-b receptor-associated protein [50]
Insulin-like growth factor 1r eceptor [50]
Immunologic/hematologic antigens
Hemoglobin 1 1[ 49]
Immunoglobulin heavy-chain constant
region g 2( Fc-IgG2 )
[49]
Interferon regulatoryf actor 8[ 49]
Interleukin 1r eceptor accessoryp rotein-like 2[ 49]
Sialic acid binding Ig-like lectin 3( CD33) [49]
Signaling lymphocytica ctivation
molecule 5( CD84)
[49]
T-cell surface antigen (CD2) [49]
Neuronal/oncologic antigens
Carcinoembryonic antigen-related cell
adhesion molecule 6
[49]
NADH dehydrogenase-like protein [348]
Neuronal cytoplasmic collapsin response
mediator protein 5
[348]
Nicotinamide/nicotinic acid mononucleotide
adenylyltransferase2
[49]
Unclassiﬁed neuronal antigen [348]
Peripheral myelin protein 22 [49]
Thyrogastric cluster antigens
Gastric parietal cell antigen [348]
Glutamic acid decarboxylase (GAD65) [348]
Proline dehydrogenase 1[ 50]
Microsomal antigen [348]
Thyroperoxidase [349]
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Although contribution of organ-non-speciﬁc antigens
to keratinocyte detachment and death in pemphigus
remainst ob ee lucidated, it is plausible to speculate
that some of them, e.g. tumorn ecrosis factor (TNF)
receptor superfamily member 5, are involved in the
activation of the extrinsic apoptotic pathway and
others,e .g. NADHd ehydrogenase-like protein, in the
activation of the intrinsic pathway [37]. Of particular
interest is av eryh igh intensity of reactivity of PV
IgG with Fc-IgG2 [49]. The fact that it has . 95%
homology with Fc-IgG 1 maye xplain ah itherto
mysterious ability of the chimeric baculoproteins
containing the constant region of human IgG1 and
Dsg 1o rD sg 3, in contrast to the extracellular portion
of Dsg 3a lone, to absorb out all disease-causing
antibodies [67–69].T hus,i tc an be concluded that
pemphigus autoimmunity is directeda gainst multiple
organ-speciﬁc and non-organ-speciﬁc proteins, some
of whicha re also targeted in othert ypes of
autoimmune diseases.
Pemphigusa utoantibodies
Explorationo fn ovel self-antigensr eactingw ith
pemphigusa ntibodiesr emains oneo ft he
top priorities in pemphigus research, because binding
of patients’ IgGs to these antigens triggersk eratino-
cyte detachment and death in PV and PF.A lthough
them echanism of blistering in patients’ skin
andm ucosai nvolvesv arious factors, including
cell-mediatedc ytotoxicity,p roteolytic enzymes, and
pro-inﬂammatorya nd pro-apoptotic cytokines, the
principal role of anti-keratinocyte antibodies in the
pathophysiology of autoimmune pemphigus has been
well documented. The major lines of evidence are as
follows: (1) occurrence of transient pemphigus-like
skin lesionsi nn eonates born by mothersw ith active
pemphigus; (2) induction of pemphigus-like pheno-
type upon passivet ransfero fp atients’ IgGs to
neonatal mice; and (3) elimination of diseasec ausing
activity of patients’ IgG fraction due to absorption
with antigenic constructs. Despite enormouse fforts
to single out an autoantibody responsible for eitherP V
or PF,n one of hitherto reported results provides
compelling evidence in favor of the monopathogenic
hypothesis of pemphigus immunopathology.
Aﬁ rsts uccessful attempt to reproduce disease
phenotype in animal model was reported by Peterson
and Wuepper [27]w ho observed small vesicles and
limiteda reaso fs uprabasal acantholysis in the skino f
neonatal mouse 36ha fter intraperitoneal injection of
av eryh igh (40mg) dose of rabbit IgG antibody raised
against the 66kD pemphigus antigen.U nfortunately,
that antibody was not afﬁnity puriﬁed on the antigenic
peptiden or wasi ts reactivity with keratinocyte
proteins characterized. Some microscopic blisters
also could be induced by pemphigusI gG eluted
from ar ecombinant amino-terminus of Dsg 3[ 67].
That IgG fraction uniquely recognized a1 30kD
protein of SDS-PAGE-resolved keratinocyte proteins.
Although the anti-Dsg 3a ntibody did not cause gross
skin blisters,t he obtainedp henotype was deemed
signiﬁcant and the antibody termed “pathogenic”.
Paradoxically, grossb listersi nt hats tudy were
induced,a lbeitb yt he pemphigus IgGf raction
depleted of Dsg 3a ntibody,i ndicatingt hat non-Dsg
3a ntibodies were actually pathogenic. This ﬁnding,
however, was interpreted as evidence that disease-
causing antibodies are directedt oo ther“ confor-
mational” epitopeso fD sg 3[ 67].
Next, it was hypothesized that the extracellular
domain of Dsg 3s hould be combined with the
Fc-portiono fh uman IgG 1 to create ap roper
conformation of the disease-speciﬁcD sg 3a ntigen
[68]. Indeed, the obtained chimeric protein absorbed
out alld isease-causing antibodiesa nd injection of
preabsorbed PV IgG fraction to neonatalm ice did
not producee xtensive skin blisters. Furthermore, the
modiﬁed chimerat hatc ontainedH is residues
attached to the Dsg3-Ig construct eliminatedd is-
ease-causing antibodies from serao fp atientsw ith
PAMS,a nd the eluted antibodies caused gross skin
blisters in neonatalm ice [70]. Thats ame strategy was
applied to create a“ proper” conformational epitope of
the Dsg1antigen capable of eliminating the disease-
causing antibodies from PF sera [69]. Surprisingly,
the antibodies eluted from neither chimeric construct
were examined for their reactivities against keratino-
cyte proteins to conﬁrmtheir unique speciﬁcityf or the
130kD Dsg3and 160kD Dsg 1a ntigens.
Successive studies demonstrated that the results
obtained in experiments with recombinant( r)Dsg1-
Ig-His and rDsg3-Ig-His chimeras that led to a
conclusion thata nti-Dsg1a nd anti-Dsg 3a ntibodies
are pathogenic in PF and PV,r espectively,w ere
complicated by the presence of non-Dsg antibodies
[18]. Figure 3s hows that antibodies eluted from the
chimeric constructs react with am ixture of keratino-
cyte proteins, includinganon-Dsg 31 30kD protein
produced in the Dsg3
2 / 2 keratinocytes used as a
sourceo fa ntigens. Noteworthy,t he fact that the
rDsg3-His construct was recognized by PVantibodies
indicated that it actually had ap roper conﬁrmation. In
contrast, the Fc-containing Dsgc onstructs evidently
did noth avep roper conﬁrmation.
These constructs were ill designed,b ecause the
ability of Fc fragment to mediatet he Fc–Fc
interactions known as Fc-mediated immune precipi-
tation [71,72] was ignored. It has been recently
demonstrated that the CH2 and CH3 domain regions
of the Fc fragment used by Amagai et al. [68–70] in
their pathogenic antibodye limination experiments
provide an interface for the antigen-unspeciﬁc binding
with another IgG moleculei ni mmune complexes
[73]. Thus,a na ntigen-unspeciﬁc,F c-mediated
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multiplea ntibodies on the chimeric Dsg baculopro-
teins. However, one of the antibodies evidently was
absorbed speciﬁcally.Ap rotein arrayh as revealed that
PV patients produce anti-Fc-IgG antibody [49].
Several attempts have been made to produce aP V
phenotype in miceb ye liciting an innate anti-Dsg3
antibody production. Immunization with recombi-
nant Dsg3 ,h owever, failed to induce acantholytic
lesionsd espite explicit antibody production [74–76].
On the otherh and, the resultso fe xperiments with
Rag2
2 / 2 mice transplanted with the Dsg 3a ntibody
producing splenocytes from either rDsg3-immunized
[77] or naive Dsg 3
2 / 2 mice [78] suggestedt he
pathogenicity of Dsg 3a ntibody in PV.S ince the
recipient mice produced limited oral acantholysis
and erosions, this mouse model was termed “active
disease” [79]. Ar ecentr eport, however, indicate that
in the Dsg3
2 / 2 splenocyte adoptive transfer model,
thee fﬁcacyo fa nti-Dsg3antibody in causing
acantholysis is , 20% [80]. Such low frequency of
functional anti-Dsg 3a ntibodies observed in the
recipient Rag2
2 / 2 mice is consistent with inability of
the majority of monoclonal murine [81] andh uman
[82,83] anti-Dsg 3a ntibodies to alter keratinocyte
adhesion. Some anti-Dsg3antibodies, however, do
causea cantholysis, albeitm orphologically different
from that found in PV patient’ss kin.
Anti-Dsg 3a ntibody produces ad esmosomal split
without keratin retraction, apparently due to steric
hindrance of Dsg 3f rom opposingc ells[ 84,85]. In
marked contrast, numerous classical [86–89] and
contemporary[ 55,90] electron microscopic studies of
PV patients’ skin vividly demonstrated that desmo-
somes remain intact till the late stages of acantholysis
when they are cleaved behind the desmosomal plaque,
due to shearing forces produced by collapsing cells,
andﬂ oat freei nt he intercellular space. Thus,
althought he alterations of keratinocyte adhesion in
recipient Rag2
2 / 2 mice are different from those taking
place in patient’s skin, these mice are still useful for
studying the regulation of adaptive immuner esponse
to Dsg 3.
Although anti-Dsg 1a nd 3a ntibodies, alone or in
combination,a re note xclusively responsiblef or
triggering intraepidermal blistering in patient’ss kin,
they have ad iagnostic utility.T he Dsg 1a nd Dsg 3
ELISAsp rovide as implea nd highlys ensitive
approach to conﬁrm the initial diagnosis of auto-
immunep emphigus and differentiate it from other
blistering diseases. The true value of ELISA results for
patient management andp rognosis, however, remains
uncertain. The Dsg 1a nd Dsg 3I gG antibody titers
do nota lways correlatew ithp emphigusd isease
activity [91,92] nor do they predict exacerbation and
relapse of the disease[ 93]. Dsg3a ntibody can be
absent in PV patientsw ith active diseasea nd present
during remission[ 94–96].F urthermore, anti-Dsg 1
or 3a ntibodiesh aveb een detected in healthy subjects,
relatives of pemphigus patients, andp atientsw ith
irrelevant medical conditions [97–109].
Early reports suggestedt hat levels of the IgG4
subclasso fD sg 3a ntibodya re associated with active
diseasea nd the IgG 1 levels with remission [110–112].
The enthusiasm aboutu sing the IgG4 autoantibody
titer for management of the disease, however, was
dampened by results of ar ecents tudy.A lthough in
patientsw ith active pemphigus,I gG4 and IgG1 were
the dominants ubclasses( 96%a nd 76%, respectively),
in clinical remission the autoantibodies predominantly
belonged to the IgG2 (75%) and IgG4 (37.5%)
subclass. Circulating IgG2 and IgG4 subclassa uto-
antibodies were also observed in 60% and 23.3%,
respectively, of healthy relatives [101]. Additionally,
some PV patients develop IgA and IgE classeso fD sg3
antibodies [113,114].
It was originally thought that the clinical phenotype
of pemphigus is deﬁned by the anti-Dsga utoantibody
proﬁlea sf ollows: anti-Dsg 1a ntibodya lone is
associated with PF,a nti-Dsg 3a ntibody alone—with
mucosal variant of PV,a nd both antibodies—with
mucocutaneous varianto fP V[ 115]. Although Dsg 1
Figure 3. Proﬁles of PV IgGs absorbed by recombinant Dsg 1a nd
Dsg 3b aculoproteinsi nt he Westernb lots of keratinocyte proteins
resolved by 7.5% SDS-PAGE. Lane 1, reaction of PV IgG puriﬁed
on the rDsg3-His construct with human keratinocytes.L ane 2, no
primarya ntibody control for lane 1. Lane 3, no primarya ntibody
control for lanes 4a nd 5. Lane 4, reaction of PV IgG puriﬁed on
the rDsg1-Ig-His construct with Dsg3
null keratinocytes.L ane 5,
reaction of PV IgG puriﬁed on the rDsg3-Ig-His construct with
Dsg3
null keratinocytes.T hepositionsofrelativem olecular mass (Mr )
markers runi np arallel lanes of each blot are shown to the left of
the respective blot. The apparent relativeM r of keratinocyte protein
bands visualized due to PV antibody binding is shownt ot he right
of lanes 2a nd 5i nt he columns designated M r .M odiﬁed from
Ref.[ 18].
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marker of PF and Dsg3antibody—that of PV,u pt o
58% of PF patients and 12% of patients with endemic
PF (FogoS elvagem) were reported to develop
antibodiesa gainst both Dsg1andD sg 3
[108,116,117]. Furthermore, it has been conclusively
demonstrated that Dsg 1a nd Dsg3t esting cannot
differentiate between various morphologic subtypes of
PV [96,118,119]. In one study,f or instance, 46% of
PV patients did not havet he PV phenotype (mucosal
or mucocutaneous) predicted by their Dsg antibody
proﬁle [118]. In another study,t he Dsg 1
þ /Dsg 3
þ
patternw as observedi n1 5% of PV patientsw ith
exclusive mucousm embrane involvement [96].
Ar ecento bservation that an increase in Dsg 1
antibody titer in aP Vp atient haso ccurreda lready
after the patient had startedt reatment and went into
clinical remission [120] supports the notion that anti-
Dsg antibodies “witness” rathert han trigger PV,i .e.
that production of these autoantibodies is the result
rathert han the causeo fe pidermal blistering in
pemphigus [121]. Reactivity of pemphigus autoanti-
bodiesw ith both extracellulara nd intracellular
domains of Dsg1a nd Dsg 3[ 122] suggests that
these antibodies are produced alreadya fter the whole
Dsg molecules have been released from the CM of
damaged keratinocytes into the intercellular space
and became available to antigen-presenting cells. The
presence of the N-terminal portion of Dsg 3i nh uman
sera [123] lends additionals upportf or the Dsg
sloughing hypothesis.
Perhaps other desmosomal cadherins are also shed
from the CM of damaged keratinocytes. The presence
of anti-Dsc1 –3 antibodiesi nP Vp atientsh as been
discovered relatively long ago [124,125], but the
interest to these antibodies was diminishedb yt he
reports that none of 45 [126] or 74 [127] PV patients
tested by ELISAh ad anya nti-Dsca ntibodies.
However, ar ecent study showing that the Dsc3loss
of function model exhibitsaphenocopy of PV [43]
suggested that anti-Dsc3antibody contributes to PV.
As expected, the monoclonal antibodyr aised against
the extracellular domain of Dsc 3c aused intraepi-
dermal blistering in an in vitro model of human skin
and al oss of cell–cell adhesion in the keratinocyte
culture [128].
In the most recent study,6out of 38 PVand1out of
85 normal serum samples immunoprecipitatedD sc 3
[129]. Furthermore, while incubation of patient’sI gG
with human keratinocytes caused the loss of inter-
cellular adhesion, adsorption with rDsc 3p revented
this effect[ 129]. Thus, while antibodiest ot he
desmosomal cadherins mayb ep laying as cavenging
role by eliminating CM debris from the intercellular
spaces of damaged epidermis theym ay obstruct
homophilic andh eterophilicb inding between the
neighboringk eratinocytes, thus contributing to
acantholysis.
The initial insult that triggersk eratinocyte damage
in pemphigusi sa pparently sustained by autoanti-
bodiest ot he cell membrane receptorsw hose
ligation causes cell shrinkage—the earliest sign of
keratinocyte detachment in pemphigus lesions
[55,86–90] that leads to ripping desmosomes off
the CM. Indeed,i th as been demonstrated that
rabbit anti-a 9A ChR antibody causes keratinocyte
shrinkagea nd roundingu p[ 36].N oteworthy,
pemphigusI gG produces similar morphologic
changes in keratinocyte monolayers[ 130].
Likewise, pharmacologic inhibition of a 3n AChR
causes keratinocytest or etract theirc ytoplasmic
aprons, shrink, andr ound up [131]. Pemphigus-like
acantholysis has also been observed due to inhibition
of keratinocyte mAChRs [130], in keeping with the
synergistic controlo fk eratinocyte adhesionb y
auto/paracrine ACht hat maintains the polygonal
shapeo fk eratinocytesa nd theira dhesion by
simultaneously activating both classeso fk eratinocyte
cholinergic receptors[ 132,133]. Hence, blockade of
any type of keratinocyte AChRsb yp emphigus IgGs
can triggera cantholysis.
Although the hypothesis of primaryi nvolvement of
autoantibodies against canonical AChR subtypes in
pemphigus pathophysiology is awaiting its in vivo
conﬁrmation, the alreadyc ompleted studies have
demonstrated essential roleo fa ntibody against the
non-canonical ligand of AChRs termed pemphaxin
[62]. Preabsorption of PV sera with recombinant
pemphaxin eliminated acantholytic activity and eluted
antibody immunoprecipitatedn ativep emphaxin.
Although anti-pemphaxina ntibodya lone did not
causes kinb listers in vivo, itsa ddition to the
preabsorbed PV IgG fraction restoredt he acantholytic
activity of passively transferred antibodies [62].
These observations indicate that pemphaxin is an
essential parto ft he pool of keratinocyte cell surface
antigens that shouldb es imultaneously targeted
by autoantibodies to induce acantholysis. The anti-
mitochondrial antibodies from different PV patients
that recognized distinct combinationso fa ntigens
with apparent MWs of 25, 30, 35, 57, 60, and
100kD evidently area lsop athogenic, because
their absorption abolished the ability of PV IgG to
causek eratinocyte detachment both in vitro and
in vivo [37].
Involvement of multiple autoantibody speciﬁcities
in pemphigus pathogenesis is explained through the
“multiple hit” hypothesis [134] as follows: anti-AChR
antibodies trigger acantholysis by weakening cohesion
of neighboring keratinocytes due to inhibition of the
physiologic control of their polygonal shape and
intercellular attachment. The affected keratinocytes
shrink, causing desmosomes to be sloughed in the
intercellular space. The adhesion molecules ﬂoating
free in the intercellular spaceb ring aboutareciprocal
production of scavenger antibodies that, in turn,
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some formation by steric hindrance. Thus,a ccording
to the multipleh it hypothesis, pemphigus results from
as ynergistic and cumulative effects of autoantibodies
targetingk eratinocyteC Ma ntigens of different
kinds including (i) molecules that regulate cell shape
and adhesion (e.g. AChRs); and (ii)m olecules that
mediate cell–cell adhesion (e.g. desmosomal cadher-
ins). Severity of the disease and exactc linical picture
dependo nt he ratio of different kinds of autoanti-
bodiesi ne achp articular patient.
In conclusion, different patients develop distinct
constellationso fa utoantibodiesw hich,t ogether
with thei ndividual’s re-epithelialization abilities,
determine clinical severityo fd isease, its natural
course, and response to treatment. The Dsg 1a nd 3
antibodies are the sensitive markerso fp emphigus, but
their primaryr ole in the pathogenesis of PF and PV,
respectively,i so verestimated. Therefore,n ot surpris-
ingly,c linical trial of the Dsg3peptides (PI-0824
vaccine) has not shown the anticipated clinical or
immunologic activity (reviewed in [135]). Apparently,
an attack by ac onstellationo fa utoantibodies
simultaneously targeting several keratinocytep roteins
is requiredt od isrupt the integrity of epidermis. The
multipleh it hypothesis reconciles ﬁndings of anti-
AChR autoimmunity with the fact that pemphigus
patients also develop autoantibodiest oa dhesion
molecules as well as various other proteins. The
hypothetical sequence of immunopathologic
and biochemical events leading to acantholysis in
pemphigus is shown in Figure 4. Future studies
shouldd eﬁne the autoantibodies that sustain an initial
insult triggering keratinocyte detachment andt hose
produced as ar esult of primaryc ell damage to clean
up the proteins released in the intercellular spaces by
damaged cells.
Regulationo fp emphigus autoimmunity
Although autoimmunity is an ormal event, auto-
immuned iseases result from an aberration of the
normal phenomenon [136]. The etiology of this
switch in pemphigus is apparently multifactorial, with
the ﬁnal common pathway being al oss of normals elf-
tolerancei nt he stratiﬁeds quamouse pithelium.
Analysis of genetic factorsc ontributingt oP Va nd
PF has shown thatt he sameg enetic regions can
contribute to both forms of the disease( reviewed in
[137]).T he HLAg enes arep robably them ost
signiﬁcantg enetic predisposition factors, because
they play an important role in the antigen presentation
process, whereas other loci may participate in an
additive or epistastic manner.
Population studies have consistently shown al ink
between certain class II HLA alleles andd istinct
ethnic groups of pemphigus patients. Ar ecent study
involving al arge cohorto fW hite European and
Indo-Asian patients with PV conﬁrmed associations
with the alleles HLA DRb 1 * 0402 and 1404, and
DQb 1 * 0302 and 0503 [138]. The DRb 1 * 1404 was
the strongestr isk factor in the Indo-Asian groupa nd
DRb 1 * 0402—in the White European group.I nW hite
Europeans, as igniﬁcant association was also shown
fort he novel allele DRb 1 * 1454 [138]. Also,i t
has been documentedt hat HLA-DRb 1 * 0402 is asso-
ciated with PV in Jewish andH LA-DQb 1 * 0503 in
non-Jewish populations [139–141].
Figure 4. Hypothetical scheme of the time course of pathobiologice vents leading to acantholysis in pemphigus.I ns tage I, antibodies to
PERPand/or cellularAChR block the physiologic control of polygonalc ell shape andintercellulara dhesion.This increases phosphorylation of
adhesion moleculesw ith their subsequent dissociation from the adhesion units on CM, and also initiates programed cell death. In stage II, the
tonoﬁlament (TF). cytoskeleton collapses and keratinocytes shrink with associated sloughing of desmosomes which elicits autoimmune
response to the desmosomal antigens. In stage III, anti-Dsg antibodies bind to their targets on the CM of keratinocytes thus precluding
formation of new intercellularj unctions.M odiﬁed from Ref.[ 55].
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bility to PF also correlates with the presence of DR4,
DR14,a nd DR1 alleles, in contrast to PV,n os ingle
DR4 or DR14 allele was found to be overrepresented
in PF patients[ 137]. The HLA-DR/DQ distributions
does not differ among PV patients according to the
presence or absence of anti-Dsg 1c oexisting with
anti-Dsg3[ 142].
Although the basis for autoimmunityi np emphigus
remainsu nrecognized, the regulation of anti-keratino-
cyte autoimmunity in PV and PF has been studied
basedo nt he assumption that Dsg 1/3 antibodies
solely represent pemphigus autoimmunity.I tw as
reportedt hat the Th1 and Th2 cell recognition of Dsg
3p eptides is restricted by HLA-DR b 1 * 0402 and/or
HLA-DQ b 1 * 0503, and that the proliferative response
of autoreactive Th cellsc an be blocked by anti-DR
and anti-DQ antibodies, respectively [143–146].
Al oss of self-tolerancea gainst Dsg 3i nb oth Tand
Bl ymphocytes was found to be required for efﬁcient
production of anti-Dsg3IgG antibodies [147–149].
The anti-Dsg3antibodyp roduction in micew as
inhibited by the anti-CD154 monoclonal antibody
that blocksC D40L–CD40 interaction [150].T he
CD8
þ Tc ellss peciﬁc for Dsg 3w ere also detected in
PV patients [151], which is in keeping with earlier
observation of the autoreactive cytotoxic Tl ympho-
cytes are sensitized to putative keratinocyte antigens in
PV patients [152].
Autoimmunity to certain epitopes of Dsg 3m ay be a
normal event, because Dsg 3-reactive Bc ellsa sw ella s
Th1 and Th2 cells are present in normali ndividuals
[97,100,101,146,151,153,154].T he presence of
autoreactive Bc ellsi se videnced by production of
anti-Dsg3antibodies by healthy relatives of PV
patients[ 97,100,101,154]. The presence of Dsg3 -
reactive Th1 cells has been demonstrated in healthy
carrierso fP V-associated HLA class II alleles, andt he
Dsg3 -reactiveT h1 clones derivedf rom these
individuals were restricted by HLA-DRb 1 * 0402 and
DQb 1 * 0503 [146,151,153].
There is ap redominance of autoreactive Dsg 3-
reactive Th1 cells in healthy individuals and Dsg 3-
reactive Th2 cellsi nP Vp atients [146]. However, Dsg
3-reactive Th2 cells are detected at similar frequencies
in acuteo nset, chronic active, and remittent PV,w hile
the numbero fa utoreactive Th1 cells exceeds that of
Th2 cells in chronic active PV [146]. Likewise, Dsg 1-
responsiveT h1 and Th2 cells were also found both in
patientsw ithP Fa nd in healthy individuals [155].
Defectsi nT regs haveb een reported in aw ide
varietyo fh umano rgan-speciﬁc autoimmune diseases
[156]. Whilet he inductiono fT reg suppressive activity
is speciﬁc and requiresa ntigenic stimulation through
T-cell receptor, the suppression exerted by Tregs is
antigen nonspeciﬁc [157]. Various Tregs can employ
distinct mechanismst oc ollaboratively regulate the
duration and magnitude of an immuner esponse
[158]. It has been postulated that active immune
suppression operates in healthy individuals possessing
Dsg 1- and Dsg 3-reactive Tc ells, and that an
imbalance of the putative relationship between auto-
reactive Th and Tregs (Tr1) cellsi sc ritical to the
development of pemphigus [159]. In support, the
CD4
þ CD25
þ hi Tregs are decreased in peripheral
bloodo fP Vp atients [160]. Furthermore, as ubset of
Dsg 3-reactive, interleukin (IL)-10-secreting Tr1c ells
was found in the majority of healthy carrierso f
PV-associated HLA class II alleles and only in , 20%
of PV patients [161]. However, ar ecent study
demonstrated thatP Vs kinl esions contain both
Foxp3-expressing cellsa nd IL-17 producing CD4
þ
cells[ 162].
Thus,deﬁciencyofT regsinPVpatient’s bloodisnot
accompaniedb yadecrease in Tregs in PV lesions, and
adecreaseinTregsinperipheral bloodmayresultfrom
accumulation of Tregs in skin lesionsa nd draining
lymphn odes [162]. Alternatively,o ra dditionally,
pemphigus autoimmunity may be triggeredv ia the
pathway involving activation of toll-liker eceptors
(TLRs). This mechanism has been suggested by a
recent demonstrationo fr eversible relapseo fP F
triggeredb yt he TLR7a gonist imiquimod [163]. In
this scenario, B-cell tolerance is broken due to ligation
of B-cell receptor andT LR by self-antigen/TLR
ligand, leading to breakage of T-cell tolerance and
activation of autoreactive Ba nd Tc ells [164].
In conclusion, regulation of Dsg 1a nd 3a nti-
body production agrees with the basic postulates of
fundamentali mmunology on Tc ell–Bc ellc o-
operation. Th1 andT h2 cellsf ound in patientsw ith
PVand healthy carrierso fP V-associated HLA class II
allelesr ecognize identical epitopeso ft he Dsg 3
ectodomain presented by antigen-presenting cells.
Ad ecrease in Tregs in peripheral bloodo fP V
patients does not validatet he postulated deﬁciency
of the immunosuppressive activity,b ecause Tregs
are present in PV lesions. Future studies of the
immunoregulatorym echanisms of PV should charac-
terize ther eputed interplay betweenT regs and
Th17 cells (Figure 5), andi dentify the role for TLRs
that can regulate function of Th1, Th2, Th17 cells,
and Tregs.
Molecular mechanisms of keratinocyte
detachment in pemphigus
Several hypotheses haveb een put forward to explain
them echanism of pemphigus acantholysis.T he
classical explanation through the hypothesis of steric
hindrance of Dsg 1- and Dsg 3-mediated adhesion
by respective antibodies [165,166] has been chal-
lengedb yn umerous reports showing activation of
speciﬁc signalingp athways in keratinocytes exposed to
pemphigus IgGs. The steric hindrance hypothesis is
basedo nt he erroneous assumptions that binding of
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[167]a nd that the phenocopies of PF andP Vi n
mouse skinc an be induced by passive transfer of PV
IgGs recognizing uniquely the desmosomal cadherins
Dsg 1a nd 3, respectively [68,69].
In fact,a lthough Dsgm olecules arei ndeed
predominantly localized to desmosomes [168], bind-
ing of PV IgG extends well beyond the desmosomes
decorating the entire surface of keratinocytes [169].
As alreadym entioned, the Dsg-Fc-IgG constructs
were found to be not speciﬁc for Dsg 1o r3a ntibodies
[18,36]. Furthermore, PF IgG has recentlyb een
shown to caused issociation of keratinocytes without
blocking Dsg1homophilic transinteraction [170].
Surprisingly, this cumulative evidence that non-Dsg
molecules are targeted by pathogenic PV IgG in the
interdesmosomal areasi sb eing interpreted as target-
ing of Dsg3located outside of the desmosomes [171].
Thea lternativeD sg 3a lterationh ypotheses
proposed by different authors[ 171–173] haveo ne
commont heme. They are basedo nt he assumption
that all outside-in signals elicited due to binding of PV
IgG to keratinocytes emanatee xclusively from Dsg3 .
To account foraveryb road spectrumo fs ignals, it was
inferred that Dsg 3c an act as both adhesion receptor
and signal transmitter [171–173].T he following
hypothetical chain of events was envisioned: (1) PV
IgG signaling is initiated by ligationo fn onfunctional
pool of Dsg3o utside of the desmosome; (2) when
ligated by an autoantibody,t hese putative nonfunc-
tional Dsg3molecules, eitherm embrane associated
or internalized or both, send signals thati mpair Dsg 3
trafﬁcking intoa nd out of desmosome; and (3)t he
supposedly impaired Dsgt rafﬁckings peciﬁcally
depletes Dsg 3f rom desmosomes without changes in
otherf unctionalp roteins.
The notion aboutp rincipal roleo fD sg 3i nP VI gG
signaling stems from experiments in whicht he whole
PV IgG fraction, rathert han afﬁnity puriﬁed patient’s
anti-Dsg 3a ntibody, was used to elicit biologic
responses [174–183].W hen interpreting results, it
was assumed that the whole plethora of PV IgG
effects, includingD sg 3e ndocytosis anda ctivation of
various signaling cascades, resulted exclusivelyf rom
Dsg 3l igation by an autoantibody.H owever, Jennings
et al. [184] have recentlyd emonstrated an explicit
biologic effect of PV IgGo nt he keratinocytes
expressing the Dsg 3m olecules whose “pathogenic”
epitopes were hidden due to cell preincubation at 4 8 C
with the anti-Dsg3monoclonal antibody AK23 that
reportedly reproduces PV phenotype [81,185] and
induces PV IgG-like signaling[ 186].
Figure 5. Hypothetical scheme of immune dysregulation in PV. Abbreviations: APC, antigen-presenting cells; IL, interleukin. Modiﬁed from
Ref.[ 339].
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secondarye vent resulting from an inside-out signaling
caused by keratinocyte response to the pathogenic
autoantibodies that deliver an initiali nsult. The
primaryr ole of anti-PEPR antibodyi nt he depletion
of Dsg 3w as suggested by an observation that binding
of PV antibodiest riggers internalization of PERP,
whiche nhancesd epletion of desmosomal Dsg 3a nd
intercellularadhesiondefects[187].Thus,endocytosis
of the immunec omplexes containing non-junctional
Dsg 3a nd depletion of Dsg 3f rom desmosomes
apparently represent two independent events, with the
former being an atural outcome of formation of
antigen–antibody complex on the CM and the latter
resulting from the inside-out signalinga ltering func-
tion andt rafﬁcking of desmosomal cadherins.
The outside-in signaling elicited due to binding of
PV IgGst ok eratinocytes proceeds viad ifferent
pathways, consistent with simultaneous ligation of
several types of cell surface receptorsb yd istinct
antibodies produced by pemphigus patients. Different
researchg roups reported engagement of Src, epider-
mal growth factor receptor (EGFR) kinase (EGFRK),
cAMP,p rotein kinases Aa nd C( PKC), phospholipase
C, mTOR, p38 MAPK, JNK, other tyrosine kinases,
and calmodulin [37,47,175,188–191].T he preferen-
tial signaling pathway downstream of targeted self-
antigensi sa pparently determined by au nique
composition of the pool of anti-keratinocyte anti-
bodiesp roduced by each PV patient,b ecause IgG
fractions from different PV patientse xhibit distinctive
time patterns of kinase activation [37].
Timing of kinase activation is critical for under-
standing the hierarchy of signaling events leading to
acantholysis. The time course studies demonstrated
that the activities of Src and EGFRK peak at 30–
60min after exposure to PV IgG [37,47], suggesting
that engagement of Src/EGFRK is ak ey step that
relays signals emanating from ligated antigens to the
intracellular effectorsa ffecting keratinocyte adhesion
and viability.
Activation of EGFRK due to binding of PV IgG to
keratinocytes is followed by phosphorylation of its
downstream substrates, the MAPk inase ERK and the
transcriptionf actor c-Jun [189]. Activation of PKC is
also one of the earliest events in PV IgG-induced
acantholysis [192]. The elevation of p38M APK
activity caused by antibodies from some PV patients
can be observed alreadya t1 5min, while the majority
of PV IgGs activate p38M APK after ap rolonged
incubation [37]. Thus,i ti sb ecoming evidentt hat an
array of interconnected signaling cascadese manating
from different cell surface antigens simultaneously
targeted by ac onstellation of patients’ anti-keratino-
cyte antibodies triggera cantholysis andk eratinocyte
death in pemphigus.
Twod ifferent approaches have been used
to elucidate involvemento fD sg 3i nt he PV
IgG-mediated signaling and deﬁne relevant pathways.
Through one approach, the Dsg1 or Dsg3 genes in
cultured human keratinocytes were silencedu sing the
RNA interference technology [47]. Transfection with
small interfering RNAst hat inhibited expression of
eitherD sg 1o rD sg 3o rb oth in allc ases blocked
approximately 50% of p38M APK activity,b ut only
slightlya ltered the PV IgG-dependent raise in Src and
EGFRK activities. To avoid any possible contribution
to PV IgG signaling by residualD sg 3p rotein, a
separate series of experiments employed keratinocytes
grown from the epidermis of neonatalD sg 3k nockout
mice[ 37]. It was documented that lack of Dsg 3d id
not affect the ability of PV IgG to activate Src and
EGFRK.
However, in the absence of Dsg 3, the PV IgG-
dependent activation of both p38 MAPK andJ NK
was signiﬁcantly reduced. Because both p38 MAPK
and JNK can be activated secondaryt ok eratinocyte
shrinkage and detachment [193–195],a nd since
keratinocyte damage in PV is associated with
activation of the cell deathp rogram (reviewed in
[196]), it was important to determine whether p38
MAPK andJ NK activationp recedeso rf ollows
launching of the apoptotic cascade. Inhibitorso ft he
executioner caspases abolished activation of JNK and
the late p38 MAPK peak [37], indicating that these
activitieswere indeed triggeredb yt he cell injuryrather
than by the PV IgG binding to keratinocyte antigens.
This supposition has been recently corroborated by a
reportt hat p38 MAPK activation occursd ownstream
at the loss of intercellular adhesion in PV [197].
Thus,a lthough thep ool of anti-keratinocyte
antibodies produced by PV patientsc ontains anti-
Dsg 1a nd/or 3a ntibodies, published studies indicate
that non-Dsg antibodies are the major contributors
to early signaling events.E arly activation of the
Src/EGFRK and PKC-dependent pathwaysi sa ppa-
rently pathogenic because it leads to acantholysis
[47,189], late activation of p38M APK is secondaryt o
cell detachment [197], whereas activation of the
cAMP/proteink inase As tepa ppears to have a
protective function [191].
The principal signaling eventleading to acantholysis
is triggered due to antibody interference with the
physiologic control of keratinocyte survival, shape,
and adhesion. Fori nstance, blocking of keratinocyte
AChRs interferesw itha uto/paracrinec ontrol of
assembly/disassembly of intercellular junctions, cell
shape,m otility,p roliferation, apoptosis, and differen-
tiation (reviewed in [198]). Both muscarinic and
nicotinic antagonists haveb een shown to wident he
intercellular spaces in epidermis and cause overt
acantholysis in vitro through the mechanism that may
involve alterations of both production and phos-
phorylationo fk eratinocyte adhesion molecules
(reviewed in [55]). It is well known that phosphoryl-
ation of adhesion molecules plays an important role in
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[199–203], and that phosphorylation of cadherin
[204–206], g -catenin[ 207], desmoplakin[ 208,209],
andDsg[210–212]isassociatedwithalossofadhesion.
Some intercellular junction proteins are phosphory-
lated on serine, someo nt yrosine, and someo nb oth
residues.T he seminalw orks by Aoyama et al.
[212,213] demonstrated that binding of PV IgG
to cell surface antigens induces phosphorylation of
Dsg3 ,i ts dissociationf romp lakoglobin,a nd
formation of Dsg 3-depleted desmosomes. These
ﬁndings were corroborated by the results showing that
in additiont oD sg 3, PV IgG also increases the level
of phosphorylation of keratinocyte E-cadherin as
well as b -, g -, and p120 catenins [214,215]. These
experimentsa lsod emonstratedt hatk eratinocyte
dyshesion correlates closely with the degree of tyrosine
phosphorylation of p120-catenin by Src and serine
phosphorylationo f b -catenin by classic PKC
isoforms [215].
The Src-dependentc ascade is also responsible for
keratinocyte shrinkage (cell volume reduction) and
keratin aggregation [47]. The cytoskeletal collapse has
been reporteda sa ne arly eventi np emphigus
acantholysis that precedes visibles eparationo f
keratinocytes [47,179,216–218]. Thus, it appears
that PV IgG-induced phosphorylation of adhesion
molecules and structuralp roteins leadst ow eakening
of intercellular junctions andc ollapse of the cytoske-
leton, respectively.T he chronological scheme of early
signaling and pathobiologic events in keratinocytes
exposed to PV IgG are shown in Figure 6.
Numerous classical andm odernc linical and
experimental studiesi np emphigusd emonstrated
thatd esmosomes separatew hent he intercellular
spaces are alreadyw idened[ 87,90,219–222].D es-
mosomes do nots plit and disappear until late in
acantholysis when keratinocytes are almost completely
separatedf rome acho ther.A te arly stages of
acantholysis,t he half-desmosomes remain invisible
because they are ﬁrmlya dhering to each other. In late
acantholysis,s omeh alf-desmosomesa dhere to each
others os trongly that they can be rippedo ff one cell
while remaining adherent to their counterparto nt he
opposite cells.
Hence,d isruptiono fi ntercellularb ridges results
fromr ipping intact desmosomes offt he plasma
membrane of collapsing keratinocytes by shearing
forces.T he intactd esmosomes ripped offf rom
neighboring cellsc an be seen ﬂoatingf ree in the
intercellular space, which is in keeping with the
sloughing of desmosomal cadherins thatg ivesr ise to
scavenging autoantibodies. The “basal cell shrinkage”
hypothesis reconciles the time course of acantholysis
in PV with the characteristic appearance of acantho-
lytic epidermis, knowna s“ tombstoning” [223].
According to this hypothesis: (1)k eratinocytes
separate because they shrink more than can be held
together by desmosomes; (2) the suprabasal clefting
occursb ecause basal cells shrink more than suprabasal
keratinocytes; and (3) pharmacologic inhibition of
the principal signalingp athways leading to cyto-
skeletal disorganization shouldp revent pemphigus
acantholysis.
Figure 6. Hypothetical scheme of early signaling steps during ﬁrst 6hafter PV IgG binding to keratinocytes and their correlation with the
major intracellular pathobiologice vents. Abbreviations: EGFR, epidermal growth factor receptor; Dsg,d esmoglein; NDAgs, non-Dsg
antigens.F rom Ref.[ 47].
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pemphigus research was elucidation of the molecular
mechanisms that selectively target basal cells in PV,a s
predicted by the basalc ell shrinkage hypothesis. Pretel
et al. [190] demonstrated that pretreatment with the
mTOR inhibitors irolimus prevented suprabasal
acantholysis in the epidermis of neonatalm ice injected
with PV IgG. In this model, PV antibodiesc aused
unopposed upregulation of mTOR selectively in basal
keratinocytes, which was associated with the appear-
ance of signs of apoptosis that were also abolished by
sirolimus [190].
Downstream of mTOR, the induction of keratino-
cyte apoptosis by PV antibodies apparently proceeds
through the c-Myc-dependent pathway [218]. c-Myc-
induced apoptosis involves caspase 9[ 224], which is
activated in keratinocytes treated with PV IgG [225].
In agreement with the fact that cyclin-dependent
kinase 2( Cdk2) is required by c-Myc to induce
apoptosis [226], PV sera induces accumulation of
Cdk2 that contributes to acantholysis in the mouse
model of PV [227]. Indeed, sirolimus has beens hown
to inhibit expression of both c-Myc [228]a nd Cdk2
[229]. Takent ogether, these observations help explain
why epidermal clefting in PValways occursj ust above
basal cells( tombstoning), despite depositiono fI gG
antibodies throughout the entire epidermis.
Both extrinsic andi ntrinsic pathwayso fc elld eath
triggered in keratinocytes by PV IgGs can lead to the
structural damagem anifested by basal cell shrinkage.
It has been documented by different research groups
that in the skin of PV patients, keratinocytes exhibit
signs of apoptosis that precede their detachment and
blister formation, andt hat PV IgG ands era induce
biomolecular markerso fa poptosis and oncosis in
keratinocytem onolayersa nd skino rgan cultures
[225,230–235]. Twog roups of PV patients, each
producing autoantibodies activating predominantly
either apoptotic or oncotic cell deathp athway,h ave
been identiﬁed [225].
The anti-PERP PV antibody may launch the cell
deathp athwaysi nk eratinocytes, because PERP
expression leads to activation of an extrinsic recep-
tor-mediateda poptotic pathwayw ith ap ossible
subsequent engagement of the intrinsic apoptotic
pathway [54]. Anti-mitochondrial PV antibodies also
can trigger intrinsic apoptotic cascade in keratinocytes
[37].O thert ypes of autoantibodiesa nd soluble
mediatorso fi nﬂammation can activate cell death
pathways in keratinocytes.D rP incelli’sg roup
demonstrated that Fasl igand( FasL) in pemphigus
sera induces keratinocytea poptosis through activation
of caspase8[231], andt hatF asL neutralizing
antibody prevents PV IgG-induced apoptosis both
in vitro and in vivo [236].
Furthermore, it hasb een shown that TNFa mRNA
is abundantly expressed in PV skin lesions [237,238];
serum TNF a levelsc orrelate closely with disease
activity and autoantibody titers[ 239,240]; and anti-
TNF a antibodyi nhibits acantholysis induced by
PV autoantibodies in vitro [237]. The synergistic
acantholytic effects of PV IgG, FasL, and TNFa were
documentedi ne xperiments with keratinocyte mono-
layers andf ull thickness equivalents of human
epidermis [241]. These mediatorso fa poptosis as
well as the increased amounts of activated kallikreins
[242] and several types of inﬂammatoryc ytokines
[237,239,243,244] found to be elevated in pemphigus
sera maya ccount for am inor acantholytic activity of
the PV serum depletedo fI gG, as reported by Cirillo
et al. [245].
Besides PV IgGs, celld eath pathways in pemphigus
can be triggered by autocrine and paracrine factors
released fromd amaged keratinocytes in situ. PV IgG
binding to keratinocytesn ot only elicits secretion of
soluble FasL but alsoi ncreases expression of Bax, Fas
receptor (FasR), coaggregation of FasL and FasR with
caspase 8i namembranal death-inducings ignaling
complex,anddownregulationoftheanti-apoptoticBcl-
2, FLIP-l,a nd theo ncosis inhibitorc alpastatin
[189,225,231,232,234,246,247].I nt urn, TNF a
inducesurokinaseplasminogenactivatormRNA[237].
It is well known that blisterﬂ uid and/or perilesional
skin of PV patientsc ontains high levels of proteases
and various inﬂammatoryc ytokines that may contrib-
ute to acantholysis [242,248–250].T hus,asimul-
taneous autoimmune attack by the threec lasses of
autoantibodies against desmosomal, mitochondrial,
and otherk eratinocyte autoantigens, such as AChRs
and PERP, mayb er equired to induce pathologic
changesi np atient’s skin.T he anti-keratinocyte
antibodies synergize with the effectorso fa poptotic
pathway FasL and TNFa as well as proinﬂammatory/ 
cytotoxic serum and tissue factors, such as serine
proteases and cytokines, that altogether overcome the
natural resistancea nd activate cell death pathways in
keratinocytes (Figure 7).
Acantholysis andc ell death (apoptosis/oncosis) are
inseparable in PV because both processes are triggered
by the same signal effectorsa ctivated due to PV IgG
binding to keratinocytes and mediatedb yt he sames et
of cell deathe nzymes. This is evident from the reports
that inhibitorso fS rc, EGFRK, p38 MAPK, and
mTOR blockb otha cantholysis anda poptosis
[1,47,176,177,189,190,215,251] and caspase inhibi-
torsp revent acantholysis both in vitro and in vivo
[190,225,246]. Moreover, it has been demonstrated
that apoptotic enzymes cleaveD sg 1, 2, and 3
[236,252,253].
Fori nstance, when PV IgG wasa ddedt o
keratinocytes in the presence of anti-FasL neutralizing
antibody,t he cleavage of the intracellular portion of
Dsg 3a nd its degradation decreased [1]. The fact
that structural damagea nd deatho fk eratinocytes in
PV are mediated by the sames et of enzymes has
justiﬁed introduction of the new term “apoptolysis” to
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induced keratinocyte damage in PV from other known
forms of cell death [1]. The apoptolysis hypothesis
links thebasalcellshrinkagetosuprabasalacantholysis
and celldeath, and emphasizes that apoptotic enzymes
contributet oa cantholysis in terms of both molecular
events andc hronologic sequence. It postulates that
cell detachment and death in PV develop through
the following ﬁve major steps (Figure 8):
. Step1 : bindingo fp athogenica ntibodiest o
keratinocytes via ar eceptor–ligandt ype of inter-
actionsendsanarrayoftheagonist-andantagonist-
like signals;
. Step 2: activation of Src, EGFRK, p38 MAPK and
mTOR, and other signaling elementsd ownstream
of ligated PVantigensa nd elevation of intracellular
Ca
2 þ ,a ltogether, initiate cell deathe nzymatic
cascades;
. Step 3: suprabasal acantholysis starts when basal
cells shrink due to reorganization of corticala ctin
ﬁlaments,c ollapse and retraction of the tonoﬁla-
ments (TFs) cleaved by executioner caspases, as
well as dissociation and internalization of inter-
cellular adhesion complexes caused by phosphoryl-
ation of adhesion molecules and their cleavage by
caspases;
. Step 4: acantholysis advances due to continued
degradationa nd massive collapse of structural
proteins by the same cell deathe nzymes, leading to
separationa nd rending of preexisting desmosomes
from the CM by shear forces, thus separating the
collapsing cells ands timulating productiono f
secondary( scavenging) antibodies;
. Step5:roundingupanddeathofacantholyticcellsin
the lower epidermal compartment follows irrevers-
ible damage of mitochondrial and nuclear proteins.
In conclusion, the mechanism of apoptolysis in PV
encompasses several tierso fe vents triggeredt hrough
distinct antigen–antibody systems. Because apopto-
lysisd evelops in as tepwise fashion, late morphologic
features of apoptosis, sucha sr ounding up, nuclear
fragmentation, and plasma membrane blebbing,d o
not become apparent until the keratinocyte death in
Step 5. Signaling mechanisms may vary from patient
to patient because au nique composition of the pool of
autoantibodies determines the principal pathway.T he
Dsg 3-dependent late peak of p38 MAPK activity and
activation of JNK represent the pathways mediating
processing and utilization of internalized Dsg 3, rather
than ap rimary downstreams ignalinge manating
from the CM.T he apoptolysis hypothesis has several
important implications:( 1) it links togetheranumber
of apparently unrelated, and previously heldc ontra-
dictory, observations on thee ventss urrounding
acantholysis;( 2) it opens new avenues of investigation
into the pathomechanism of pemphigus; and (3)i t
creates new approaches to the treatment of pemphigus
basedo ni nterfering with or blocking the signaling
pathways ande nzymatic processes that lead to
blistering.
Figure 7. Hypothetical scheme of signaling events mediating keratinocyte damage in PV. Abbreviations: AMPVAb, anti-mitochondrial
PVantibody; Cs, caspase; FasL, Fasl igand; FasR, Fasr eceptor; MRPVAg,m itochondria-related PV antigen; NO,n itric oxide; OPVAb, PV
antibodies of other speciﬁcities, including anti-AChR and anti-PERP antibodies;O PVAg,o ther types of putativeP Va ntigens; PVAb,
PV antibody; TNFa ,t umor necrosis factor a .M odiﬁed from Ref.[ 37].
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The high-dose, long-terms ystemicg lucocorticoid
therapy remainst he mainstay of currentt herapy of PV
and PF patients. Corticosteroidh ormones (usually
prednisone tablets)a re essential to establish control of
PV during the acute stage [2,254,255]. Optimal
dosingp roved to be variable and couldn ot be
predicted at the outset in any given patient [4]. Some
patientsr espond rapidly and completely to treatment
with moderated oses of oral prednisone (1mg/kg/day),
others are rather refractorya nd require muchh igher
doses. If there is no response after 5–7d ays, the dose
is increased by 50–100% [256,257]. Once the control
of the diseasei sa chieved (lack of new lesions,
epithelialization of existing erosions and negative
Nikolskiy sign [258,259]),t he prednisone dosage is
decreased in a“ logarithmic fashion”,i .e. by 10–20%
every7 –15d ays.C hronic PV patientsw ith disease
exacerbation are treated exactlyt he same way as new
patients, i.e. prednisone dose is increased until disease
controli sa chieveda nd than tapered [256,257].
The ﬁrst reporto fa dministration of glucocorticoids
to ap emphigus patient is datedt o1 940 [260], i.e.
some 25 yearse arlier than pemphigus antibodies were
discovered. Adrenocortical extractw as triedf or
treatment, because it hadb een noticed that pemphi-
gus is associated with changes in patients’ blood
chemistryc haracteristic of abnormal (deﬁcient)
function of the adrenal gland producing cortisone.
Thes ynthetic cortisonew as introduced to the
treatment of pemphigus approximately 10 yearsl ater
[261]. Prior to the introduction of therapy with oral
corticosteroids in the 1950s, the diseaseh ad ad ismal
natural course with a5 0% mortality rate at 2y earsa nd
100% mortality rate by 5y earsa fter the onseto ft he
disease. Although there has been as igniﬁcant decrease
in mortality nowadays [262], it remains at ar elatively
high level of approximately 12% [263], with death
being almost invariably related to complications of
therapy.
The early adversee ffects of systemicg lucocorticos-
teroidst hata re essentially unavoidablei nclude
enhanced appetite, ﬂuid, and salt retention leading
to weight gain and neuropsychiatric disorderss uch as
Figure 8. Hypothetical scheme of keratinocyte apoptolysis in PV.S tep 1: apoptolysis is triggered by binding of autoantibodies to the PV
antigens capable of transducing apopotolytic signals from the keratinocyte plasma membrane, such as PERP and AChRs.S tep 2: outside-in
signaling from ligated antigens launches the cell death cascades.S tep 3: collapse and retraction of the TFs cleaved by executioner caspases and
dissociation of interdesmosomal adhesion complexes caused by phosphorylation of adhesion moleculesr esult in basal cell shrinkage, most of
desmosomesremainintact.Step4:massivecleavageofcellularproteinsbyactivatedcelldeathenzymesleadstocollapseofthecytoskeletonand
tearing off desmosomes from the CM with subsequent productiono fs cavenging (i.e. secondary) autoantibodies mainly to sloughed adhesion
molecules. Step 5: suprabasal acantholytic cells die rendering at ombstone appearance to surviving basal cells.M odiﬁed from Ref.[ 1].
Myths and Realities of Pemphigus 21emotional lability,i nsomnia,i rritability,a nxiety,
depression, euphoria, hyperactivity,a nd manic epi-
sodes. Delayed andi nsidious adversee ffects that
dependo nc umulative dose include the Cushingoid
appearance, hypothalamic–pituitary–adrenals up-
pression, menstrual disorders, hyperlipidemias, ather-
osclerosis, cardiovascular events, fatty liver, cataracts,
growth retardation, osteoporosis, osteonecrosis, myo-
pathy,m uscle crampsa nd weakness, and skin bruising
andt hinning[ 264,265].R area nd unpredictable
adversee ffects are glaucoma, pancreatitis and pseu-
dotumor cerebri.T reatment of pemphigus patients
with corticosteroids can also unmask or aggravate
concomitanta cne vulgaris, diabetes mellitus hyper-
tension, and peptic ulcer disease.
The goal of pemphigus research is to develop an
effective treatment modality thatw ould allow to
achieve and maintainc linical remission without the
need to use systemic corticosteroids. Although this
goal has not been reached yet, as ubstantial progress
was made toward development of steroid-sparing
regimens. Basedo na ssumption that glucocorticoids
treat pemphiguso wing to their immunosuppressive
properties, most of the clinical researchh as been
focused on the immunosuppressive therapy. The
following is ac hronological sequenceo ft he reports
of steroid-sparing drugs andt herapeutic modalities in
thet reatmento fp emphigus. Immunosuppressive
cytotoxic drugs: methotrexate [266], azathioprine
[267], cyclophosphamide [268], chlorambucil[ 269],
and mycophenolate mofetil [270]. Immunomodula-
tors:h eparin [271],c yclosporine[ 272],T -cell
immunocorrection viap hotophoresis [273],h igh-
dose intravenous g globulin, i.e. IVIg [274], rituximab
[275]a nd daclizumab [276]. Anti-inﬂammatory
drugs: gold [277], dapsone [278], doxycycline [279],
tetracycline [280], minocycline [281], tranilast [282],
and thalidomide [283]. Extracorporeal autoantibody
eliminations: plasmapheresis [284], plasma exchange
[285], hemocarboﬁltration[ 243],a nd protein A
immunoadsorption [286].
Unfortunately,t hese therapiesd on ot allow
reliable control of acutep emphigus without systemic
glucocorticosteroids, indicatingt hati na ddition to
immunosuppression the therapeutic actiono fc orti-
costeroids in pemphigusi ncludes otherm echanisms,
such as directa nti-acantholytic effecto nk eratino-
cytes. Moreover, althought here is ab ulk of evidence
that PV is predominantly aT h2-type autoimmune
disease, at least with regard to the anti-Dsg3antibody
production[ 113,144,159,287], thed atao nt he
mechanisms of immunomodulatorya ction of gluco-
corticosteroidsc ounterintuitively demonstrate that
these drugs foster Th2 polarization of CD4
þ Tc ells
[288–290].
Direct anti-acantholytic effects of the corticoster-
oids methylprednisolone andh ydrocortisone on
keratinocytes were discovered in in vitro experiments,
in which high doses of these drugs blocked PV IgG-
induced acantholysis [291,292]. Because antibody-
producing cells were notp resent in cultures, these
drugs couldn ot exhibit their anti-acantholytic effects
bywayofactinguponlymphocytes.Subsequentinvivo
experimentsd emonstratedt hata dministration of
methylprednisolone signiﬁcantly decreased the extent
of acantholysis in the epidermis of 3–5-day-old nude
micei njected with PV IgG [214]. This was in keeping
with thec linical observations that blistering in
pemphigus patients stops within 24–48h rs after
initiation of ah ighd ose, “pulse” therapyw ith
methylprednisolone or dexamethasone [293–296],
while the major decline in autoantibody titerso ccurs
3–4 weeks after initiation of glucocorticoid therapy
[297]. It is well known thatp emphigus therapy
improves disease earlier than decreasing the antibody
titers[ 298].
Also, local administration of a0 .05% clobetasol
propionate cream cani nitially control cutaneous
lesionsi nm ild cases of PV [299]. The directe ffects
of corticosteroids that can protect keratinocytes from
PV IgG mayi nclude alterations in gene expression,
as revealed by aD NA microarraya ssay [214]. PV
IgG downregulated and methylprednisoloneu pregu-
lated expression of the genes encoding the keratino-
cyte adhesionm oleculesD sg 3a nd periplakin,
regulatorso fc ell cycle progression and apoptosis,
differentiation markers, protein kinases and phospha-
tases, serine proteases and their inhibitors, ands ome
otherg enes.F urthermore,m ethylprednisolone
blocked phosphorylation of Dsg 3, E-cadherin, and
b -a nd g -catenins induced by PV IgG [214].
These pharmacologic effects of methylprednisolone
help explain the dose-dependent therapeutic actiono f
corticosteroids in pemphigusp atients. It is well known
that extremely high corticosteroidd oses are sometime
required to attain control of acantholysis in the acute
stage of disease. Thus,i na ddition to their immuno-
suppressive and anti-inﬂammatorya ctions in pem-
phigus, glucocorticoids can also regulate adhesion and
viability of keratinocytes through ac ombination of
their genomica nd non-genomic effects.
Historically,t he earliest attempt to treat pemphigus
patientsb yp rotecting the target cells( keratinocytes)
from the PV IgG-induced damagew as made using
the proteinase inhibitors aprotinin (Contrykal) and
1 -aminocaproica cid [242]. Af ew yearsl ater, Dobrev
et al. [300] administered p -aminomethylbenzoic acid.
In both studies, the addition of protease inhibitors
allowed to achieve therapeutic effects at lower doses of
systemic corticosteroids, thus decreasing the risk for
adverser eactions. More recently, TNFa inhibitors
haveb een tried.
Clinical beneﬁt in PV was reported fore tanercept
(Enbrel) [301–303] andi nﬂiximab( Remicade)
[304,305], and for adalimumab (Humira) in IgA
pemphigus [306]. The p38 MAPK inhibitorK C-706
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be aborted due to severe adverse reactions. According
to Dr Rubenstein’sr eporta tt he JC Bystryn
pemphigus &p emphigoid Meeting [307], KC-706
had been administered orally to 15 patientsw ith PV.
One half of the patients experienced ap artial response
to treatment, while the remainingp atients eitherf ailed
to improveo re xperienced worsened disease.
Oral nicotinamide (niacinamide) is often used
to treatp emphigusp atients [280,281,308,309].
Although the exactm echanism of its therapeutic
actioni np emphigusr emainsu nknown, the efﬁcacyo f
4% nicotinamide gel in the treatment of cutaneous
erosions of PV patientsi nadouble-blind,p lacebo-
controlled study[ 310] suggestst hat it exerts a
pharmacologic effecto nt argetc ells. In lesional skin,
nicotinamide can stimulate keratinocyte adhesion and
facilitate epithelialization through its cholinomimetic
action[ 311] that includes both stimulation of ACh
release [312] and inhibition of AChd egradation by
acetylcholinesterase [313].
The importance of nicotinergic stimulation for the
treatment of pemphigus was ﬁrst suggested by the
reporto faPV patient whose disease worsened when
he stopped smoking and improved shortly after he
resumeds moking [314]. The epidemiologic studies
conﬁrmedt he beneﬁciale ffect of smokingo n
pemphigus. Brenner et al. [315] reported that 25.9%
of 126 patientsw ere smokers vs. 48.5% of controls.
According to Sullivane ta l. [316], only 15.3% of 59
patientsw ere current or former smokers,c omparedt o
47.4% in the general population. These ﬁndings have
recently been validated in as tudy involving 199
patientsw ith PV,1 1w ith PF,a nd 205 control subjects
[317]. Also, it has been reportedt hat smokersw ith PV
achieve partial remission more frequently than non-
smokers at the end of the 1st year of treatment, and
that the number of patients in remission at the end of
the 2nd year of therapy is signiﬁcantly higherf or
smokers than for non-smokers[ 318]. The cigarette
smoke contains the nicotinergic agent nicotine that
not only upregulates epithelialization in vitro [131] but
also facilitates healing of skine rosions [319]. In
additiont os timulation of epithelialization, nicotine
may exhibit its therapeutic effect in pemphigus by
affecting the immune system.
Experimental studiesd emonstrated that activation
of nAChRs suppresses B-cella ctivation[ 320],
abrogates phytohemagglutinin-dependent upregula-
tion of TNF a and IFNg receptorsi nTcells [321],
inhibitse xpression of the TNF a ,I L-6 and IL-18
genes,a nd upregulates IL-10 production in macro-
phages [322]. Furthermore, the nicotinergic signaling
facilitates T-cell polarization toward Th1 lineage,
inhibitsT h17 differentiation, and upregulates Tregs
[323,324]. Altogether, these immunopharmacologic
effects of nicotine mayb ea ble to correct the immune
dysregulation characteristic of pemphigus (Figure 5).
The perspective for the development of steroid-
sparing therapy employing cholinergic drugs is very
promising,b ecause cholinergica gonistso fb oth
nicotinic and muscarinic classesh avea lreadys hown
their therapeutic activities in pemphigus patients. The
nAChRs in keratinocytes can be directly activated by
pyridostigmine bromide (Mestinon) [325]. Besides its
underappreciated nicotinergic action, pyridostigmine
bromide is reversible acetylcholinesterase inhibitor
[326] that can elevate tissuel evelso fa uto/paracrine
ACh, thus augmenting signalingt hroughb oth
muscarinica nd nicotinic pathways in thec ells
secreting ACh,l ike humank eratinocytes[ 327].
Pyridostigmine bromide has been shown to antagon-
ize the effects of PV antibodies in both in vitro [328]
and in vivo experiments [329]. Most importantly,a
clinical trial of Mestinon in the treatment of eight
pemphigusp atients brought encouragingr esults
[330]. Three patientss howed av eryg ood response,
andﬁ ve patients did nots howa ny signiﬁcant
improvement. One patient was able to discontinue
glucocorticosteroids and immunosuppressive medi-
cations, andc ontrol the disease using Mestinon only.
In contrast to glucocorticosteroids and protease
inhibitorst hatc an only blockb ut notr everse
acantholysis [291,331],m uscarinic agonists both
prevented cell detachment and restoredt he integrity
of keratinocyte monolayerse xposed to PV IgGs,
the serine proteinase trypsin or the calciumc helator
EDTA[ 130].T hese observations indicatet hat
them uscarinic effectss temf rom activationo f
the epithelialization program that comprises both the
adhesive andt he migratory functions of keratinocytes
(reviewed in [55,198]).C onsistent with the ability of
the cholinomimetic carbachol to prevent acantholysis
and skinb listering in the neonatala thymic nude
micew ith passively transferred PV IgGs [329], a
double-blind,p lacebo-controlleds tudy showed thera-
peutic activityo ft he muscarinic agonistp ilocarpine
4% gela pplied to skin erosions of PV patients [332].
Pilocarpine preferentially binds to and activate the
M 1 molecular subtype of keratinocyte mAChRs [333]
that has been recently found to be speciﬁcally targeted
by PV antibodies [49]. Pilocarpine blocks PV IgG-
induced phosphorylationo fp 120- and b -catenins in
keratinocytes, because it elevates both serine/threo-
nine andt yrosine phosphatase activities[ 215].
Furthermore, the anti-acantholytic activity of pilocar-
pine synergizes with that of the a 7n AChR agonist
AR-R17779 thatb oth activates tyrosine phosphatase
and inhibitsS rc [215]. Taken together, these ﬁndings
identify novel paradigm of regulation of signaling
kinases associated with cholinergic receptorsa nd
provide mechanistice xplanationo ft herapeutic
activity of cholinomimeticsi nP Vp atients.
Al arge variety of steroid-sparing effects reported
thus fari nt he literature suggests that it should be
possible to replace corticosteroids by combining the
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can provide for simultaneous inhibition of antibody
production andp rotection of keratinocytesf rom
autoantibody action. Unfortunately,s uch putative
combination has not been devised yet, though a
combination of rituximaba nd IVIg allows to treat
certain PV patients without corticosteroids [334].
Most recently,i th as been reported that the
mTOR inhibitor sirolimus( Rapamune,R apamy-
cin w )c ombinedw ithI VIga llowed rapida nd
complete withdrawal of systemicg lucocorticosteroids
in aP Vp atient whod eveloped diseasee xacerbation
that could notb ec ontrolledw ith4 0mg/day of
prednisone [120]. Sirolimus is an aturally occurring
lipophilic microcyclic lactone isolated from Strepto-
myces hygroscopicus discovered at Rapa Nui (Easter
Island). It bindst oi mmunophilin and FK binding
protein-12.
Thes irolimus–FKBP-12 complex targetst he
290kD serine–threonine kinaseo ft he phosphoinosi-
tide 3-kinases/Akt pathway termed mTOR [335].
Sirolimus exhibits potent immunosuppressive
activity due to suppression of T- and B-cell activation
andI L-2- andI L-4-dependent proliferationv ia
inhibition of new ribosomal protein synthesis and
arresto ft he G1–Sphase of the cell cycle [336]. In PV,
theimmunosuppressive actionofsirolimusmaybecome
therapeuticw heni ti st aken foraperiodo ft ime. The
rapidhealingoftheskinlesioninthereportedcaseofPV
patienti nt he acutes tage of disease[ 120],h owever,
suggests that it hadadirect effect on keratinocytes that
protectedt hemf roma utoantibody action.
As already mentioned, the mTOR pathway is
activated in keratinocytes exposed to PV IgG and
mTOR inhibitionp revents acantholysis in the murine
passive transfer model of PV IgG [190]. Additionally,
sirolimus mayp revent damage of keratinocytes and
enforce their adhesive function by inhibiting reorgan-
ization of the actin cytoskeleton andp hosphorylation
of focala dhesion proteins, andu pregulating
E-cadherine xpression [337,338]. The clinical trial
of sirolimus in pemphigusp atientsi sc urrently
underway at University of California Irvine (http://
clinicaltrials.gov/ct2/show/NCT01313923).
Table II. Hypotheses and realities in the knowledge of pemphigus.
Hypotheses Realities
The epidermal integrity is mediated
exclusively by the Dsg 1a nd 3a dhesion
molecules
Neither Dsg 1n or Dsg 3c an solely sustain keratinocyte adhesion in epidermis.P atients with
striate palmoplantarkeratodermafeaturing N-terminaldeletioninDsg1d onotdevelopskin
blisters [350]. In turn, the conditionalD sc3
null mutant mouse developsP Vp henotype
despite the presence of intact Dsg 3[ 43]. If the integrity of epidermis would rely exclusively
on Dsg 1a nd 3, the epidermis should disintegrate to as ingle cell suspension in the
PV patients who develop both anti-Dsg 1a nd 3a ntibodies (Figure 2)
Acantholysis is PV is caused by steric
hindrance of Dsg 3b ya utoantibodies
Electron microscopic studies of limited acantholysis produced by anti-Dsg 3a ntibody in
murine epidermis revealed that steric hindrance of Dsg 3l eads to ad esmosomal split without
keratin retraction [84,85]. The ultrastructural changes in the skin of PV patients are quite
different. Desmosomes remain intact till the late stages of acantholysis when they are cleaved
behind the desmosomal plaque, due to shearing forces produced by collapsing cells, and
ﬂoat free in the intercellular space [55,86–90]. Acantholysis is PV results from
PV antibody-dependent signaling events collectively described by the terma poptolysis [1]
Clinical and histological features of PF
and PV can be reproduceds olely by
Dsg 1a nd 3a ntibodies, respectively
The experiments using the Dsg1-Ig and Dsg3-Ig chimeras that absorbed out all disease causing
pemphigus antibodies,t hus giving ar ise to an otion that anti-Dsg 1/3 antibodies are the sole
cause of pemphigus,w ereﬂ awed by the presence of non-Dsg antibodies (Figure 3)
An interplay between Dsg 1a nd 3
antibodies determines the
mucocutaneous phenotype in patients
with autoimmunep emphigus
PF patients can developa ntibodies against both Dsg 1a nd Dsg 3[ 108,116,117], and the
Dsg 1/3 antibody patternd oes not match the predicted morphologic phenotype
of PV [96,118,119]
The titers of anti-Dsg 1o r3a ntibodies
correlate closely with the severely of the
disease
The Dsg 1/3 antibody titers do not correlate with disease activity [91–93]. While Dsg 3
antibody can be absent in PV patients in active stage of disease, it can be present in
PV patients during remission [94–96] as well as in healthys ubjects and patients with
irrelevant medical conditions [97–109]
The sera of patients with autoimmune
pemphigus contain autoantibodies only
to the Dsg 1/3 targets
More than 50 organ-speciﬁc and non-organ-speciﬁc proteins haveb een reported to date as
speciﬁc targets for autoantibodies produced by PV and/or PF patients (Table I)
Systemic corticosteroids treat pemphigus
patients exclusively by inhibiting
autoantibody production
The therapeutic effect of “pulse” therapy with methylprednisolone commencesw ithin a
few days, whereas autoantibody titers decline within 3–4w eeks [294–296]. The rapid
therapeutic effect is apparently mediated by direct anti-acantholytic action of
glucocorticosteroids that protects keratinocytes from an autoantibody-induced
damage [214]
Paraneoplastic pemphigus (PNP) is a
variant of classical pemphigus
PNP is not related to PV and PF,b ut represents ac linical variant of the paraneoplastic
autoimmune multiorgan syndrome (PAMS) in which patients, in addition to small airway
occlusion, may display as pectrum of at least ﬁve clinical variants, i.e. pemphigus like
(a.k.a. PNP), pemphigoid like, erythema multiforme like, graft vs. host disease like,
and lichen planus like [10,12,13]
S. A. Grando 24In conclusion, corticosteroids remain an essential
componento fp emphigust reatment. Earlya nd
aggressiveu se of corticosteroidsi sr equired to
decrease the duration of treatment and avoid relapses.
Adjuvant drugs allow ad ecrease in the total dose of
corticosteroids. The natural course of pemphigus has
improved with new therapies. Cholinomimetics can
achieve as teroid-sparing effect in pemphigus patients
by both stimulating epithelialization and inhibiting
autoimmune aggression. The dualistic pharmacologic
actiono fs irolimus that affects both effectorso f
autoimmunitya nd targetc ellsa pparently mediatesi ts
therapeutic effect in pemphigus. Further elucidation
of the molecular mechanisms mediating aberrant
signaling along the mTOR pathway in PV should
improveo ur understandingo ft he pathogenesis and
lead to novel therapeutic approachesf or the develop-
mento fs teroid-free treatment of pemphigus.
Summary
(1) Recent advances of knowledge on pemphigus
autoimmunity scrutinize old dogmas,r esolve
controversies, and open novel perspectives for
treatment (Table II).
(2) The initial insult is sustained by the autoanti-
bodiest ot he cell-membraner eceptor antigens
triggering thei ntracellulars ignalingb yS rc,
EGFRK, PKC, phospholipase C, mTOR, p38
MAPK,o ther tyrosine kinases, and calmodulin
that cause basalc ells hrinkage andr ipping
desmosomes off the CM.
(3) Autoantibodies synergize with the effectorso f
apoptotic and oncoticp athways, serine proteases
and inﬂammatoryc ytokines to overcome the
natural resistance and activate the cell death
program in keratinocytes.
(4) The process of keratinocyte shrinkage/detach-
menta nd death via apoptosis/oncosish as been
termed apoptolysis to emphasizet hati ti s
triggeredb yt he same signal effectorsa nd
mediated by the same cell deathe nzymes.
(5) Although ah igh-dose, long-terms ystemicg luco-
corticoid therapy remainst he mainstay of current
treatment of patientsw ith PV or PF,c ausing
severe adverse effects, as ubstantial progress has
been made towardd evelopment of steroid-
sparing therapies combining the immunosup-
pressive andd irecta nti-acantholytic effects.
(6) Theo nset of acantholysis in drug-induced
pemphigusi np atients takinga ngiotensin-
converting enzyme inhibitors, such as captopril,
apparently involves ad rop in the concentration of
auto/paracrine ACht hat sustainsk eratinocyte
shape and cohesiveness, due to as trongu pregu-
lation of the AChd egrading enzyme acetylchol-
inesterase[ 351].
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